PL2297100T3 - Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego - Google Patents

Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego

Info

Publication number
PL2297100T3
PL2297100T3 PL09747531T PL09747531T PL2297100T3 PL 2297100 T3 PL2297100 T3 PL 2297100T3 PL 09747531 T PL09747531 T PL 09747531T PL 09747531 T PL09747531 T PL 09747531T PL 2297100 T3 PL2297100 T3 PL 2297100T3
Authority
PL
Poland
Prior art keywords
tetrahydrocyclopenta
indole
androgen receptor
receptor modulators
modulators
Prior art date
Application number
PL09747531T
Other languages
English (en)
Inventor
Prabhakar Kondaji Jadhav
Venkatesh Krishnan
Euibong Jemes Kim
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2297100T3 publication Critical patent/PL2297100T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/94[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL09747531T 2008-05-16 2009-05-14 Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego PL2297100T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5372208P 2008-05-16 2008-05-16
PCT/US2009/043875 WO2009140448A1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators
EP09747531A EP2297100B1 (en) 2008-05-16 2009-05-14 Tetrahydrocyclopenta[b]indole androgen receptor modulators

Publications (1)

Publication Number Publication Date
PL2297100T3 true PL2297100T3 (pl) 2013-03-29

Family

ID=40847864

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09747531T PL2297100T3 (pl) 2008-05-16 2009-05-14 Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego

Country Status (18)

Country Link
US (1) US8486943B2 (pl)
EP (1) EP2297100B1 (pl)
JP (1) JP5603327B2 (pl)
KR (1) KR101278788B1 (pl)
CN (1) CN102026974B (pl)
AU (1) AU2009246348B2 (pl)
BR (1) BRPI0912394A2 (pl)
CA (1) CA2724629C (pl)
CY (1) CY1113341T1 (pl)
DK (1) DK2297100T3 (pl)
EA (1) EA019713B1 (pl)
ES (1) ES2396612T3 (pl)
HR (1) HRP20120917T1 (pl)
MX (1) MX2010012436A (pl)
PL (1) PL2297100T3 (pl)
PT (1) PT2297100E (pl)
SI (1) SI2297100T1 (pl)
WO (1) WO2009140448A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
DK3122426T3 (da) 2014-03-28 2023-04-03 Univ Duke Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
KR102397890B1 (ko) 2016-06-22 2022-05-12 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
AU2019297421A1 (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
EP4175647A1 (en) * 2020-07-06 2023-05-10 Crescenta Biosciences Antiviral use of fabp4 modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO2003014082A1 (en) 2001-08-09 2003-02-20 Eli Lilly And Company Cyclopenta ` b ! indole derivatives as spla2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US7728150B2 (en) 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
CA2588384A1 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
AR052674A1 (es) 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
JP5204650B2 (ja) 2005-06-24 2013-06-05 イーライ リリー アンド カンパニー アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators

Also Published As

Publication number Publication date
AU2009246348A1 (en) 2009-11-19
KR101278788B1 (ko) 2013-06-25
US20110039855A1 (en) 2011-02-17
MX2010012436A (es) 2010-12-06
JP5603327B2 (ja) 2014-10-08
CN102026974A (zh) 2011-04-20
PT2297100E (pt) 2013-01-24
CN102026974B (zh) 2013-08-28
JP2011520903A (ja) 2011-07-21
ES2396612T3 (es) 2013-02-22
DK2297100T3 (da) 2012-12-17
AU2009246348A8 (en) 2010-12-16
HRP20120917T1 (hr) 2012-12-31
EA201071317A1 (ru) 2011-06-30
CA2724629C (en) 2014-08-19
AU2009246348B2 (en) 2012-04-12
WO2009140448A8 (en) 2010-01-07
US8486943B2 (en) 2013-07-16
WO2009140448A1 (en) 2009-11-19
KR20100132551A (ko) 2010-12-17
CY1113341T1 (el) 2016-06-22
SI2297100T1 (sl) 2013-02-28
EP2297100A1 (en) 2011-03-23
BRPI0912394A2 (pt) 2016-07-26
EP2297100B1 (en) 2012-10-31
EA019713B1 (ru) 2014-05-30
CA2724629A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
PL2297100T3 (pl) Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego
HRP20181229T1 (hr) Spojevi koji moduliraju androgene receptore
HK1259082A1 (zh) 大麻素受體調節劑
HK1134089A1 (en) Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
HRP20130374T1 (en) Pyrrolidin-2-one derivatives as androgen receptor modulators
IL208185A0 (en) Chemokine receptor modulators
GB0701992D0 (en) Grehlin Receptor Modulators
ZA201101707B (en) Novel imidazolidine compounds as androgen receptor modulators
ZA201002268B (en) Benzothiazoles as ghrelin receptor modulators
HRP20130409T1 (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
EP2303275A4 (en) STANDARD RECEPTOR MODULATORS
GB0811212D0 (en) CB1 Receptor Modulators
PL2288612T3 (pl) Modulatory receptora GABAA
ZA200907546B (en) New progesterone receptor modulators
GB0813350D0 (en) Cannabinoid receptor modulators
GB0807710D0 (en) Receptor and modulators thereof